There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer
申请人:BRISTOL-MYERS SQUIBB COMPANY
公开号:US10399932B2
公开(公告)日:2019-09-03
There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine-2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
申请人:GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
公开号:US10787442B2
公开(公告)日:2020-09-29
Provided are IDO inhibitor compounds of Formula I and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases.
本文提供了式 I 的 IDO 抑制剂化合物及其药学上可接受的盐、它们的药物组合物、它们的制备方法以及它们用于预防和/或治疗疾病的方法。
INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER
申请人:Bristol-Myers Squibb Company
公开号:EP3277670A1
公开(公告)日:2018-02-07
MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE
申请人:GlaxoSmithKline Intellectual Property Development
Limited